Ratings Bangkok Dusit Medical Services

Equities

BDMS

TH0264A10Z04

End-of-day quote Thailand S.E. Other stock markets 03:30:00 03/05/2024 am IST			5-day change	1st Jan Change
29 ^THB	+0.87%		+0.87%	+4.50%

24/04	Bangkok Dusit Medical Services Public Company Limited Announces Appointment of Kongkiat Kespechara as Executive Committee Member	CI
05/04	Bangkok Dusit Medical Services Public Company Limited Approves Final Dividend, Payable on 22 April 2024	CI

Summary

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
The company presents an interesting fundamental situation from a short-term investment perspective.

Strengths

The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
The company returns high margins, thereby supporting business profitability.
The company is in a robust financial situation considering its net cash and margin position.
Over the past year, analysts have regularly revised upwards their sales forecast for the company.
Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
For the last few months, EPS revisions have remained quite promising. Analysts now anticipate higher profitability levels than before.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Over the past twelve months, analysts' opinions have been strongly revised upwards.
Considering the small differences between the analysts' various estimates, the group's business visibility is good.
Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
Historically, the company has been releasing figures that are above expectations.

Weaknesses

With an expected P/E ratio at 29.35 and 26.9 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
With an enterprise value anticipated at 4.21 times the sales for the current fiscal year, the company turns out to be overvalued.
The company appears highly valued given the size of its balance sheet.
The valuation of the company is particularly high given the cash flows generated by its activity.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Healthcare Facilities & Services

	1st Jan change	Capi.	ESG Refinitiv
BANGKOK DUSIT MEDICAL SERVICES	+4.50%	12.38B	B
AIER EYE HOSPITAL GROUP CO., LTD.	-18.46%	16.57B	B+
IHH HEALTHCARE	+4.31%	11.73B	B+
ENCOMPASS HEALTH CORPORATION	+24.72%	8.4B	B
RAMSAY HEALTH CARE LIMITED	-2.64%	7.63B	A-
MOUWASAT MEDICAL SERVICES COMPANY	+20.04%	7.16B	D
THE ENSIGN GROUP, INC.	+4.17%	6.63B	B-
GLOBAL HEALTH LIMITED	+46.90%	4.58B	-
DALLAH HEALTHCARE COMPANY	-5.70%	4.22B	-
BURJEEL HOLDINGS PLC	-4.82%	4.18B	-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders